This PR is another confirmation that Management continues to struggle to stay on track with timelines, no solid info in PR, it's like throwing darts at the calendar. Unfortunately the China agreement has options to own the IP with or without a vaccine ......how will effect that the Merck/AE37 trial and the shady current valuation of 500M. Let's hope Dawson James won't withdraw the IPO.